National Institute for Clinical Excellence Recommends QbTest to Aid Diagnosis of ADHD in Youth
July 30 2024 - 7:55AM
Business Wire
Global Leader in ADHD Objective Testing
Improves Access to Care for Patients in the U.S. and UK
The National Institute for Clinical Excellence (NICE), a UK
government-funded, non-departmental public body that aims to
establish guidelines for clinical best practice, issued its
recommendation for the National Health Service (NHS) to use
Qbtech’s industry-leading objective tests to improve diagnostic
wait times for children and youth, age six to 17. The approval for
using QbTest alongside traditional diagnostic methods enables more
children to get diagnosed within six months of their initial
assessment, addressing the long waiting periods many families are
experiencing.
Results from the AQUA clinical trial found that using the QbTest
alongside a standard clinical assessment for ADHD resulted in
faster diagnostic decisions being made for a more significant
proportion of people within six months of their first assessment
appointment when QbTest results were available, compared with when
they were not. It also resulted in clinicians being able to rule
out ADHD in more cases.
“The evidence we have to date, further cemented by the recent
NICE recommendation to the NHS, highlights the importance of
objective ADHD testing in improving overall ADHD care,” shared Dr.
Angela LaRosa, a Charleston-based developmental and behavioral
pediatrician. “As a specialist in developmental and behavioral
pediatrics, incorporating objective ADHD assessments in my practice
has been crucial for increasing access to care, and we now have
better data for making informed care decisions, including treatment
optimization and monitoring."
QbTest is an FDA-cleared, market-leading computer-based test
with motion tracking that measures core ADHD symptoms—inattention,
impulsivity, and hyperactivity. The results are analyzed and
presented in an easy-to-read visual report comparing them to a
normative control group of the same age and sex at birth who do not
have ADHD.
“ADHD diagnosis rates are rising globally, with the CDC
reporting a 16% increase from 2016 to 2022,” said Mikkel Hansen,
Chief Medical Officer at Qbtech. “The increase in demand has put a
severe strain on healthcare systems, leading to significant delays
in diagnosis that are having far-reaching effects on children and
their families. Our objective tests add necessary safeguards to the
diagnostic process and enable clinicians to complete a
comprehensive assessment effectively and efficiently. We’re honored
to be recognized by NICE and excited to further our work with the
NHS to improve access to ADHD care in the UK and with similar
organizations worldwide.”
Qbtech’s objective ADHD testing technology is used by more than
12,000 clinicians across 44 states in the U.S. and at the national
level by organizations such as the NHS in England in over 120
sites. The company has been documented in more than 40 independent
studies, showing benefits across the patient care pathway,
including improved access to care, elevated clinician confidence,
better identification of treatment effects than self-rating, and
standardization of care across multiple disciplines.
About Qbtech
Founded in 2002, Qbtech is a privately-owned Swedish company
that has developed leading solutions and products for improving the
identification, diagnosis, treatment, and follow-up of patients
living with ADHD. Qbtech has operations in 14 countries and has
offices in Stockholm, Houston, and London. Qbtech is an
award-winning company recognized for its innovation, most recently
winning the 2022 HSJ Partnership Award for the ‘Best Mental Health
Partnership with the NHS.’ For more information about Qbtech, visit
www.qbtech.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240730274142/en/
Hilari Barton, Trevelino/Keller Hnbarton@trevelinokeller.com
404-214-0722 x 130